How satisfied are MS patients with a new injection form of their treatment?

This study is following people with multiple sclerosis who are starting ocrelizumab as a subcutaneous injection (under the skin) for the first time. Researchers want to understand how satisfied patients are with this new way of receiving their MS treatment and whether it affects nerve damage markers in the blood. By tracking your experience over 12 months, the study aims to learn whether this injection method works well for patients in real-world settings.

Many MS patients have been taking this medication as an infusion in a clinic, which takes several hours. This study exists to see whether patients prefer and are satisfied with the new subcutaneous injection form, which can be given at home and takes less time.